Global Molecular Diagnostics Partnering 2010-2018 report provides the reader with the following key benefits:
In-depth understanding of Molecular Diagnostics deal trends since 2010
Access to headline, upfront, milestone and royalty data
Analysis of the structure of Molecular Diagnostics agreements with numerous real life case studies
Detailed access to actual Molecular Diagnostics contracts entered into by leading biopharma companies
Identify most active Molecular Diagnostics dealmakers since 2010
Insight into terms included in a Molecular Diagnostics partnering agreement, with real world examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
'
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in Molecular Diagnostics dealmaking
2.1. Introduction
2.2. Molecular Diagnostics partnering over the years
2.3. Most active Molecular Diagnostics dealmakers
2.4. Molecular Diagnostics partnering by deal type
2.5. Molecular Diagnostics partnering by therapy area
2.6. Deal terms for Molecular Diagnostics partnering
2.6.1 Molecular Diagnostics partnering headline values
2.6.2 Molecular Diagnostics deal upfront payments7
2.6.3 Molecular Diagnostics deal milestone payments
2.6.4 Molecular Diagnostics royalty rates
Chapter 3 – Leading Molecular Diagnostics deals
3.1. Introduction
3.2. Top Molecular Diagnostics deals by value
Chapter 4 – Most active Molecular Diagnostics dealmakers
4.1. Introduction
4.2. Most active Molecular Diagnostics dealmakers
4.3. Most active Molecular Diagnostics partnering company profiles
Chapter 5 – Molecular Diagnostics contracts dealmaking directory
5.1. Introduction
5.2. Molecular Diagnostics contracts dealmaking directory
Chapter 6 – Molecular Diagnostics dealmaking by technology type
Chapter 7 – Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
Appendices
Appendix 1 – Molecular Diagnostics deals by company A-Z
Appendix 2 – Molecular Diagnostics deals by stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation
Appendix 3 – Molecular Diagnostics deals by deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Litigation
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Warranty
Appendix 4 – Molecular Diagnostics deals by therapy area
Appendix 5 –Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering
Table of figures
Figure 1: Molecular Diagnostics partnering since 2010
Figure 2: Active Molecular Diagnostics dealmaking activity– 2010 to 2018
Figure 3: Molecular Diagnostics partnering by deal type since 2010
Figure 4: Molecular Diagnostics partnering by disease type since 2010
Figure 5: Molecular Diagnostics deals with a headline value
Figure 6: Molecular Diagnostics deals with an upfront value
Figure 7: Molecular Diagnostics deals with a milestone value
Figure 8: Molecular Diagnostics deals with a royalty rate value
Figure 9: Top Molecular Diagnostics deals by value since 2010
Figure 10: Most active Molecular Diagnostics dealmakers 2010 to 2018
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events
